The Business Of Biotech Podcast
-
Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
6/19/2026
On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma.
-
Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
6/12/2026
On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks about why biotech drug launches so often miss expectations, and how to build an integrated commercialization plan that holds up with physicians, patients, and payers.
-
The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry
6/5/2026
On this week's episode of the Business of Biotech, Tyler Menichiello, chief editor at Bioprocess Online, host of the Better Biopharma podcast, and my Life Science Connect (LSC) colleague, convenes the broader LSC editorial team once again for a midyear discussion on what's happening now in the life sciences industry, and what's to come in the second half of the year.
-
Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.
5/28/2026
On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen.
-
Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane
5/20/2026
On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization.
-
Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D.
5/14/2026
On this week's episode of the Business of Biotech, Marinna Madrid, Ph.D., Cofounder, Board Member, Chief Product and Regulatory Officer at Cellino, talks about scaling up an automated manufacturing process she co-invented for personalized autologous induced pluripotent stem cell (iPSC) therapies using laser-activated substrates and AI.
-
Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.
5/7/2026
On this week's episode of the Business of Biotech, Wyatt McDonnell, Ph.D., cofounder and CEO at Infinimmune, talks about how single-cell biology and computational rigor led to the formation of Infinimmune, and a new way to discover human-derived antibody drugs.
-
From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.
4/29/2026
On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals, talks about how antisense oligonucleotides (ASO) graduated from a late-1980s lab concept to real RNA-targeting medicines, and why Ionis stuck with a difficult modality despite multiple setbacks.
-
Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
4/24/2026
On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries.
-
The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
4/16/2026
On this week's episode of the Business of Biotech, five-time public company CFO and seven-time public company board member Allan Shaw talks about why FDA decision-making feels less predictable, and how that uncertainty is reshaping clinical trial strategy, investor behavior, and the innovation ecosystem.